Clinical trial · Observational
Radiofrequency Ablation Treatment of Low-Risk Papillary Thyroid Carcinomas
Thermoablation Treatment of Malignant Thyroid Carcinomas
NCT07506161CI-TRIAL-00114144completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Researchers in this study aim to prove the safety and efficacy of radiofrequency ablation in the treatment of a carefully selected low-risk papillary thyroid microcarcinoma patient group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Papillary Thyroid Microcarcinoma | Thyroid Gland Papillary Microcarcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiofrequency ablation alone | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The number of patients without clinical evidence of a tumor on ultrasound and cytology on the treatment site
- timeFrame
- 24 months
- description
- We measure the number of patients without clinical evidence of a papillary thyroid microcarcinoma at the treatment site, evaluated with a (B-mode) ultrasound scan and a contrast-enhanced ultrasound scan of the whole tyroid and cytology reports from a fine needle aspiration from the site of the treatment at 24 months post-ablation.
Secondary outcomes (2)
- measure
- Number of patients with adverse effects
- timeFrame
- 24 months
- description
- Adverse effects measured during and after the procedure according to SIR AE
- measure
- Volume reduction ratio
- timeFrame
- 24 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with cytologically confirmed papillary thyroid carcinoma with the longest diameter of less than or equal to 10 mms in T1aN0M0 clinical stage without metastases and without cytological signs of aggressivity AND * Patients objecting to both surgery and active surveillance Exclusion Criteria: * History of or active disease: neck irradiation, stroke, CV disease, CNS vascular malformation, any malignant disease, immunocompromised state, recurrent laryngeal nerve paresis, organ failure * extrathyroidal extension of tumor (including capsular) * pregnancy * lesion less than 5 mm close to the danger zone * safety margin could not be obtained (min 2mm) * uncontrolled hyperthyroidism * uncontrolled hypothyroidism * primary hyperparathyroidism * calcitonin or serum calcium over the threshold on a repeat blood test
References
Publications (0)
Data not yet available
No reference posted for this study.